Early evolution of plasma soluble TNF-α p75 receptor as a marker of progression in treated HIV-infected patients

AIDS Research and Human Retroviruses

Volumn 24, Issue 11, 2008, Pages 1383-1389

  Morlat, P ^a,b,c,g   Pereira, E ^b,c   Clayette, P ^d   Derreudre Bosquet, N ^d   Ecobichon, J L ^e   Benveniste, O ^f   Saves, M ^b,c   Leport, C ^e   Raffi, F ^h   Chene G ^h   Salamon, R ^h   Moatti, J P ^h   Pierret, J ^h   Spire, B ^h   Brun Vezinet F ^h   Fleury, H ^h   Masquelier, B ^h   Peytavin, G ^h   Garraffo, R ^h   Costagliola, D ^h   Dellamonica, P ^h   Katlama, C ^h   Meyer, L ^h   Salmon, D ^h   Sobel, A ^h   more..

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INSERM   (France)

^d INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^e BICHAT HOSPITAL   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^g HÔPITAL SAINT ANDRÉ   (France)

^h Hôpital Saint André ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; GLUTATHIONE; PROTEIN P75; THROMBOCYTE ACTIVATING FACTOR; TRIPEPTIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA P75 RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MALE; MEASUREMENT; PLASMA; PRIORITY JOURNAL;

EID: 57049085258     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0293     Document Type: Article

References (43)

1. Godfried MH, van der Poll T, Weverling GJ, et al.: Soluble receptors for tumor necrosis factor as predictors of progression to AIDS in asymptomatic human immunodeficiency virus type 1 infection. J Infect Dis 1994;169:739-745.
2. Godfried MH, van der Poll T, Mulder JW, et al.: Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection. J Acquir Immune Defic Syndr Human Retrovirol 1995;10:531-539.
3. Fahey J, Taylor J, Detels R, et al.: The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990;322:166-172.
4. Zangerle R, Steinhuber S, Sarcletti M, et al.: Serum HIV-1 RNA levels compared to soluble markers of immune activation to predict disease progression in HIV-1-infected individuals. Int Arch Allergy Immunol 1998;116:228-239.
5. Aukrust P, Muller F, Lien E, et al.: Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: Persistent TNF activation is associated with virologic and immunologic treatment failure. J Infect Dis 1999;179:74-82.
6. Saves M, Morlat P, Chene G, et al.: Prognostic value of plasma markers of immune activation in patients with advanced HIV disease treated by combination antiretroviral therapy. Clin Immunol 2001;99:347-352.
7. Stein DS, Lyles RH, Graham NM, et al.: Predicting clinical progression or death in subjects with early-stage human immunodeficiency virus (HIV) infection: A comparative analysis of quantification of HIV RNA, soluble tumor necrosis factor type II receptors, neopterin, and beta2-microglobulin. Multicenter AIDS Cohort Study. J Infect Dis 1997;176:1161-1167.
8. Bonnet F, Saves M, Morlat PH, et al.: Correlations of soluble interleukin-2 and tumor necrosis factor type II receptors with immunologic and virologic responses under HAART. J Clin Immunol 2002;22:75-82.
9. Prescott S, Zimmerman G, and McIntyre T: Platelet-activating factor. J Biol Chem 1996;268:17381-17384.
10. Kravchenko V, Pan Z, Han J, Herbert J, Ulevitch R, and Ye R: Platelet-activating factor induces NF-kappa B activation through a G protein-coupled pathway. J Biol Chem 1995;270:14928-14934.
11. Le Naour R, Clayette P, Henin Y, et al.: Infection of human macrophages with an endogenous tumour necrosis factor-alpha (TNF-alpha)- independent human immunodeficiency virus type 1 isolate is unresponsive to the TNF-alpha synthesis inhibitor RP 55778. J Gen Virol 1994;75:1379-1388.
12. Nakamura M, Honda Z, Izumi T, et al.: Molecular cloning and expression of platelet-activating factor receptor from human leukocytes. J Biol Chem 1991;266:20400-20405.
13. Tjoelker L and Stafforini D: Platelet-activating factor acetylhydrolases in health and disease. Biochem Biophys Acta 2000;1488:102-123.
14. Pietarinen-Runtti P, Lakari E, Raivio K, and Kinnula V: Expression of antioxidant enzymes in human inflammatory cells. Am J Physiol Cell Physiol 2000;278:118-125.
15. Herzenberg L, De Rosa S, Dubs J, et al.: Glutathione deficiency is associated with impaired survival in HIV disease. Proc Natl Acad Sci USA 1997;94:1967-1972.
16. Garaci E, Palamara A, Ciriolo M, et al.: Intracellular GSH content and HIV replication in human macrophages. J Leukoc Biol 1997;62:54-59.
17. Staal F, Roederer M, and Herzenberg L: Intracellular thiols regulate activation of nuclear factor kappa B and transcription of human immunodeficiency virus. Proc Natl Acad Sci USA 1990;87:9943-9947.
18. Le Moing V, Thiébaut R, Chêne G, et al.: Plasma HIV RNA as predictor of long-term increase of CD4+ cell counts in human immunodeficiency virus-infected patients initiating a protease-inhibitor containing regimen. J Infect Dis 2002;185:471-480.
19. Centers for Disease Control and Prevention: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41:1-19.
20. Hughes MD, Johnson VA, Hirsch MS, et al.: Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med 1997;126:929-938.
21. Mellors J, Munoz A, Giorgi J, et al.: Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-954.
22. Graham NM: The role of immunologic and viral markers in predicting clinical outcome in HIV infection. AIDS 1996;10:S21-25.
23. Engelberts I, Moller A, Schoen G, van der Linden C, and Buurman W: Evaluation of measurement of human TNF in plasma by ELISA. Lymphok Cytok Res 1991;10:69-76.
24. Aderka D, Engelmann H, Maor Y, Brakebusch C, and Wallach D: Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992;175:323-329.
25. Kalinkovich A, Geleziunas R, Kemper O, et al.: Increased soluble tumor necrosis factor receptor expression and release by human immunodeficiency virus type 1 infection. J Interferon Cytokine Res 1995;15:749-757.
26. Benito JM, Lopez M, Lozano S, Martinez P, Gonzales-Lahoz J, and Soriano V: CD38 expression on CD8 T lymphocytes as a marker of residual virus replication in chronically HIV-infected patients receiving antiretroviral therapy. AIDS Res Hum Retroviruses 2004;20:227-233.
27. Ondoa P, Koblavi-Dème S, Borget MY, Nolan ML, Nkengasong JN, and Kestens L: Assesment of CD8 T cell immune activation markers to monitor response to antiretroviral therapy among HIV-1 infected patients in Côte d'Ivoire. Clin Exp Immunol 2005;140:138-148.
28. Steel A, John L, Shamji MH, et al.: CD 38 expression on CD8 T cells has a weak association with CD4 T-cell recovery and is a poor marker of viral replication in HIV1-infected patients on antiretroviral therapy HIV Med 2008;9:118-125.
29. Wang C, Wen T, Routy J-P, Bernard NF, Sekaly RP, and Watts TH: 4-1BBL induces TNF receptor-associated factor 1-dependent Bim modulation in human T cells and is a critical component in the costimulation-dependent rescue of functionally impaired HIV-specific CD8 T cells. J Immunol 2007;179:8252-8263.
30. Herbein G and Khan KA: Is HIV infection a TNF receptor signalling-driven disease? Trends Immunol 2008;29:61-67.
31. Pérez-Casanova A, Husain K, Noel RJ Jr, Rivera-Amill V, and Kumar A: Interaction of SIV/SHIV infection and morphine on plasma oxidant/antioxidant balance in macaque. Mol Cell Biochem 2008;308:169-175.
32. Jariwalla RJ, Lalezari J, Cenko D, Mansour SE, Kumar A, Gangapurkar B, and Nakamura D: Restoration of blood total glutathione status and lymphocyte function following lipoic acid supplementation in patients with HIV infection. J Altern Complement Med 2008;14:139-146.
33. Stephensen CB, Marquis GS, Douglas SD, Kruzich LA, and Wilson CM: Glutathione, glutathione peroxidase, and selenium status in HIV-positive and HIV-negative adolescents and young adults. Am J Clin Nutr 2007;85:173-181.
34. Merrill JE, Koyanagi Y, and Chen IS: Interleukin-1 and tumor necrosis factor alpha can be induced from mononuclear phagocytes by human immunodeficiency virus type 1 binding to the CD4 receptor. J Virol 1989;63:4404-4408.
35. Merrill JE, Koyanagi Y, Zack J, Thomas L, Martin F, and Chen IS: Induction of interleukin-1 and tumor necrosis factor alpha in brain cultures by human immunodeficiency virus type 1. J Virol 1992;66:2217-2225.
36. Westendorp MO, Shatrov VA, Schulze-Osthoff K, et al.: HIV-1 Tat potentiates TNF-induced NF-kappa B activation and cytotoxicity by altering the cellular redox state. EMBO J 1995;14:546-554.
37. Kedzierska K and Crowe SM: Cytokines and HIV 1: Interactions and clinical implications. Antiviral Chem Chemother 2001;12:133-150.
38. La Maestra L, Zaninoni A, Marriott JB, Lazzarin A, Dalgleish AG, and Barcellini W: The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro. Clin Exp Immunol 2000;119:123-129.
39. Moreira A, Corral L, Ye W, et al.: Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro. AIDS Res Hum Retroviruses 1997;13:857-863.
40. Jacobson JM, Greenspan JS, Spritzler J, et al.: Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997;336:1487-1493.
41. Wanchu A, Bhatnagar A, Bambery P, et al.: Prevention of opportunistic infections in HIV infection by pentoxyphylline. Indian J Med Res 2006;124:705-708.
42. Kuller L and SMART Study: Elevated levels of interleukin-6 and D-dimer are associated with an increased risk of death in patents with HIV. 15th Conference on Retroviruses and Opportunistic Infections, Boston, February 3-6, 2008, Abstract 139.
43. Salazar-Gonzalez JF, Martinez-Maza O, Aziz N, et al.: Relationship of plasma HIV-RNA levels and levels of TNF-alpha and immune activation products in HIV infection. Clin Immunol Immunopathol 1997;84:36-45.